In addition, REMOVE also suggests that the use of CytoSorb in this setting is safe, with a similar adverse event profile to standard of care therapy. ![]() Although the pre-specified primary outcome of the study was neutral, we demonstrated CytoSorb’s ability to reduce cytokines. Torsten Doenst: „The REMOVE topline results presented at the EACTS meeting contribute significant and valuable information on the intraoperative use of CytoSorb in patients undergoing valve replacement surgery for infective endocarditis. Diab: „no signal for harm due to the use of CytoSorb in patients undergoing surgery for infective endocarditis.“
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |